Time: 08:00 – 10:30 CET
Venue: Cirio Law Firm, Biblioteksgatan 9, Stockholm
Attendance is complimentary, but registration is required as seats are limited.
Event Overview
In a rapidly changing global market, Hong Kong continues to strengthen its position as a leading international financial center and the key gateway to Mainland China and Asia. With major reforms in its capital markets, including new listing regimes for biotech and specialist technology companies, and the Stablecoin Ordinance announced on 1 August 2025, Hong Kong offers unique opportunities for Swedish startups, growth companies, and listed firms to access funding, strategic partnerships, and new market channels.
This seminar brings together senior executives and experts from J.P. Morgan, HKEX, Cirio Law Firm, Sigmoid Ventures, and Frédéric Cho Advisory to discuss the evolving capital landscape, opportunities for dual listings, venture funding, digital assets, and cross-border collaboration across innovation ecosystems. Participants will gain valuable insights into how Hong Kong can serve as a strategic platform for growth and expansion in Asia.
Program
1. Breakfast and Registration (30 min)
– Complimentary breakfast & networking
2. Welcoming Remarks (5 min)
– Björn Segerblom, Honorary Chairman, HKCCSE
Welcoming words from the organizer
3. Introduction of Moderator & Theme (5 min)
– Hanna Raftell, Partner, Sigmoid Ventures
Overview of seminar flow and key topics.
4. Keynote 1 – Global Capital Flows and Emerging Market Trends (15 min)
– David Lau, Managing Director, J.P. Morgan Hong Kong
Global perspective on capital market movements, regional liquidity trends, and investor sentiment across US, Europe, and Asia.
5. Keynote 2 – HKEX: New Directions in Fundraising and Global Listings (15 min)
– Johnson Chui, Managing Director, Hong Kong Exchanges & Clearing
Reforms, dual listings, biotech and specialist tech opportunities for international companies.
6. Keynote 3 – Hong Kong as a New Hub for Life Science Investment (15 min)
– Dr. Chuen Yan Leung, Life Science Investor & Industry Advisor
Strategic positioning and investment collaboration between Nordic and Asian life science sectors.
7. Keynote 4 – The Future of FinTech: Bridging Stockholm & Hong Kong (15 min)
– Hanna Raftell, Partner, Sigmoid Ventures
FinTech, digital finance, and cross-border regulation trends.
8. Keynote 5 – China’s Economic Trajectory and Hong Kong’s Role (15 min)
– Frédéric Cho, Founder, Frédéric Cho Advisory AB
New opportunities for cooperation between Nordics and China-HK through the capital markets.
9. Panel Discussion & Audience Q&A – Hong Kong as the Gateway for Capital, Markets, and Innovation (30 min)
– All speakers, moderated by Hanna Raftell, with Per Hedman, Partner, Cirio Law Firm & Head of Life Science
10. Closing Remarks (5 min)
-Dr. Eric Zhang, Chairman, HKCCSE
Summary and appreciation.
Björn Segerblom
Permanently based in Hong Kong since a large number of years, previously also living in Japan, Philippines, Switzerland and his native country Sweden, Björn Segerblom has extensive international industrial experience from senior executive positions as well as board assignments in listed companies.
His wide experience spans over chemical, turnkey contracting, industrial explosives and mechanical engineering industries, as well as certification, inspection and testing services for industries and governments, plus extensive exposure also to international incubation and start-up communities in several high-tech and life science sectors, including regular interaction with government and business agencies in primarily Hong Kong and Europe.
Björn’s current engagements include as Board member in listed Obducat AB, a pioneering international leader in nanoimprint lithography serving a variety of global high-tech industries, including semiconductors, where he is also Chairman of its Audit Committee.
With a long engagement also with the Board of Hong Kong Chamber of Commerce in Sweden, including previously as its Chairman, Björn is now Honorary Chairman, Chair Nomination Committee and serving as an active Hong Kong Representative.
Björn has a Master of Science degree in Chemical Engineering from Chalmers University of Technology, Gothenburg, Sweden.
Ms. Hanna Raftell:
Hanna is an investor and co-founder of an initiative building something new in the Nordic venture space — with a focus on fintech and energy efficiency at the seed and Series A stages, across Europe. With a strong background in emerging technologies, Hanna has been at the forefront of AI, blockchain, and decentralized finance, focusing on how these technologies are reshaping the financial system.
Driven by a deep belief in the transformative power of infrastructure innovation, Hanna has led investments and advisory work across tokenized assets, next-gen payment rails, stablecoins, and decentralized identity. Her work spans from traditional capital markets to cutting-edge developments in Web3 and the metaverse — always with a critical lens on scalability, regulation, and long-term impact.
A frequent advisor to startups and LPs navigating the future of finance, Hanna brings a unique blend of technical insight and strategic foresight.
Dr. Chuen Yan Leung
Dr. Chuen Yan Leung is currently Partner (Healthcare Investments) at Value Partners Group, one of Hong Kong’s largest independent asset management firms. Chuen Yan is also managing partner of Silver Dart Capital, a boutique healthcare investment firm. He was previously a private equity professional at EQT Group, a Swedish global investment organization, and Lead Scientist at Procella Therapeutics (Now SmartCella), a stem cell therapeutics start-up based in Sweden.
Dr. Leung is currently a non-executive director of Insilico Medicine, non-executive director of Phase Scientific, and the Vice President of the Hong Kong Biotechnology Organization. Dr. Leung received his PhD in Stem Cell Biology from the University of Cambridge, and BSc in Biochemistry from Imperial College London.
David PW Lau:
David PW Lau is Co-Head of China Investment Banking Coverage and Head of APAC Healthcare Investment Banking
at J.P. Morgan, responsible for global investment banking strategies for clients in Mainland China and Hong Kong.
He joined J.P. Morgan in 1995. David has served various functions during his career at J.P. Morgan, including Equity
Capital Markets, Mergers & Acquisitions, China Corporate Finance, and Hong Kong Investment Banking, and
worked on a large number of Capital Markets and M&A transactions. David has been serving as a member of
Chairmen Pool of Listing Review Committee of the HKEX, a member of the SFC REIT Committee and SFC Process
Review Panel, a member of the Economic Advancement Expert Group of the Chief Executive’s Policy Unit (CEPU)
of the Hong Kong Government, and a Council member and Audit Committee member of The University of Hong
Kong.
Prior to joining J.P. Morgan, David worked in Private Equity. David also worked at both the Listing Division of the
HKEX and the Hong Kong SFC between 2002 and 2004, and was responsible for IPO vetting and formulating capital
market policies. David was a member of the Listing Committee of HKEX from 2017 to 2023, responsible for
providing policy advice and taking decisions on listing matters. Between January 2016 to June 2017, David was an
Associate Member of the Central Policy Unit of the Hong Kong Government.
David graduated from the University of California at Los Angeles majoring in Business Economics.
Johnsson Chui
Managing Director and Head of Global Issuer Services Hong Kong Exchanges and Clearing Limited (HKEX)
Mr Johnson Chui joined HKEX as Managing Director and Head of Global Issuer Services in September 2024.
In his role, Mr Chui leads HKEX’s Global Issuer Services teams based in Hong Kong, Mainland China, London and Singapore, driving the Group’s efforts to further diversify and expand its listed issuer base.
Mr Chui has more than 25 years of experience working in international capital markets. Prior to joining HKEX, he held senior positions at Nomura, where he was Managing Director, Vice Chairman of Investment Banking and Head of Equity Capital Markets, Asia ex-Japan.
Prior to Nomura, Mr Chui spent nearly 18 years at Credit Suisse, where he was Head of Equity Capital Markets for Asia-Pacific and a member of the Operating Committees for Global Equity Capital Markets and Asia Pacific Investment Banking & Capital Markets. He has also held senior investment banking roles at Citigroup and Goldman Sachs in Hong Kong.
Mr Chui holds Bachelor of Laws and Bachelor of Commerce (Finance) degrees from the University of New South Wales in Australia.
Frédéric Cho
Frédéric Cho, Founder of Frederic Cho Advisory AB, Vice Chairman of Sweden-China Trade Council (SCTC).
Frédéric is the only person in the Nordic region having worked in all fields of China’s financial sector (banking, insurance and investment banking) but also in life science and media. He has lived and worked for 18 years in Beijing, Wuxi, Shanghai, Taipei, Hong Kong and Singapore.
Frédéric Cho Advisory AB focuses on strategic advisory related to investments and business development between the Nordic region and Greater China, Korea, Singapore and Japan.
Per Edman:
Per Hedman is head of Cirio’s Life Science, Healthcare & Food group and is recognized as a leading lawyer in the life science field. Per regularly advises clients in transactional matters as well as complex regulatory issues that arise in respect of life science, healthcare and food.
Per has extensive experience advising clients in connection with Swedish and cross-border M&A and VC investments particularly with regard to life science, healthcare and food. Per regularly advises Swedish and foreign clients on complex regulatory and market access matters in his areas of expertise, and his command of life science issues cover both medical devices and pharma.
In addition, Per has significant experience in supporting clients in complex contractual matters whether it be of an operational nature (such as capex investment, supply of raw materials, manufacturing, and distribution) or regarding R&D. Per’s work in this regard is primarily focused in the life science, food, and forestry sectors.
Dr. Eric Zhang
Dr. Eric Zhang is an innovation leader and cross-border business strategist with over 25 years of international experience spanning Sweden, China, the Netherlands, Canada, and Singapore. He is the Chairman of the Hong Kong Chamber of Commerce in Sweden, where he drives initiatives to strengthen business and capital flow between the Nordics and Hong Kong.
A Ph.D. from KTH Royal Institute of Technology in Stockholm, Dr. Zhang is also the founder of InnoXventure Sweden AB, focusing on cross-border investment facilitation, technology commercialization, and sustainable materials innovation. His career combines deep-tech entrepreneurship, IP strategy, and international business development — bridging Nordic innovation with Asian markets and investors.
